Key Takeaways
- Biogen announces a $2 billion investment to expand its North Carolina operations at Research Triangle Park.
- The company currently employs over 1,500 workers and an additional 400 contractors in the area.
- This expansion aims to modernize manufacturing capabilities and support Biogen’s drug pipeline while benefiting the local life sciences community.
Major Investment by Biogen
Biogen, a global leader in biotechnology, announced a significant $2 billion investment at its Research Triangle Park (RTP) facility in North Carolina. This expansion will reinforce Biogen’s commitment to manufacturing innovation, as the company seeks to enhance its operational capabilities in the region.
Currently, Biogen employs more than 1,500 workers along with approximately 400 contractors at its RTP campuses. This makes Biogen the largest biotechnology employer in North Carolina and one of the top five biopharmaceutical employers in the United States.
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, emphasized the company’s longstanding relationship with the RTP community. She noted that Biogen’s manufacturing presence has been central to its success and the development of impactful treatments for patients worldwide. The investment aims to modernize manufacturing capabilities, which will enable Biogen to efficiently roll out its drug pipeline and ensure a resilient supply for patients.
Biogen first established its roots in Research Triangle Park in 1995, and since then, it has played a crucial role in the local economy and the broader life sciences sector. The investment is expected to support not only Biogen’s growth but also contribute to the development of a skilled workforce in North Carolina.
Overall, this $2 billion investment represents Biogen’s commitment to advancing healthcare and underscores the importance of the Research Triangle region within the biotechnology landscape.
The content above is a summary. For more details, see the source article.
